Meeting
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
Authors
Bradley Alexander McGregor
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Bradley Alexander McGregor , Jiaming Huang , Wanling Xie , Wenxin Xu , Mehmet Asim Bilen , David A. Braun , Tian Zhang , Rana R. McKay , David F. McDermott , Hans J. Hammers , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT04413123
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4520)
DOI
10.1200/JCO.2023.41.16_suppl.4520
Abstract #
4520
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
First Author: Sylvie Lorenzen
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.
First Author: Vanessa Anne Eulo
Poster
2020 ASCO Virtual Scientific Program
Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.
First Author: Bradley Alexander McGregor